Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana M. Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Janne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. CostaGordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok Kin Wong, Peter S. Hammerman

Research output: Contribution to journalArticle

406 Citations (Scopus)

Abstract

Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidate mechanisms of adaptive resistance, we analyse the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma. In tumours progressing following response to anti-PD-1 therapy, we observe upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3), in PD-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade. Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure. These data suggest that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.

Original languageEnglish (US)
Article number10501
JournalNature Communications
Volume7
DOIs
StatePublished - Feb 17 2016

Fingerprint

T-cells
Mucin-3
death
Up-Regulation
Immunoglobulins
antibodies
T-Lymphocytes
Blocking Antibodies
therapy
Tumors
Therapeutics
lungs
tumors
Antibodies
Biomarkers
Tumor Microenvironment
biomarkers
Treatment Failure
Ligands
mice

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., ... Hammerman, P. S. (2016). Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications, 7, [10501]. https://doi.org/10.1038/ncomms10501

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. / Koyama, Shohei; Akbay, Esra A.; Li, Yvonne Y.; Herter-Sprie, Grit S.; Buczkowski, Kevin A.; Richards, William G.; Gandhi, Leena; Redig, Amanda J.; Rodig, Scott J.; Asahina, Hajime; Jones, Robert E.; Kulkarni, Meghana M.; Kuraguchi, Mari; Palakurthi, Sangeetha; Fecci, Peter E.; Johnson, Bruce E.; Janne, Pasi A.; Engelman, Jeffrey A.; Gangadharan, Sidharta P.; Costa, Daniel B.; Freeman, Gordon J.; Bueno, Raphael; Hodi, F. Stephen; Dranoff, Glenn; Wong, Kwok Kin; Hammerman, Peter S.

In: Nature Communications, Vol. 7, 10501, 17.02.2016.

Research output: Contribution to journalArticle

Koyama, S, Akbay, EA, Li, YY, Herter-Sprie, GS, Buczkowski, KA, Richards, WG, Gandhi, L, Redig, AJ, Rodig, SJ, Asahina, H, Jones, RE, Kulkarni, MM, Kuraguchi, M, Palakurthi, S, Fecci, PE, Johnson, BE, Janne, PA, Engelman, JA, Gangadharan, SP, Costa, DB, Freeman, GJ, Bueno, R, Hodi, FS, Dranoff, G, Wong, KK & Hammerman, PS 2016, 'Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints', Nature Communications, vol. 7, 10501. https://doi.org/10.1038/ncomms10501
Koyama, Shohei ; Akbay, Esra A. ; Li, Yvonne Y. ; Herter-Sprie, Grit S. ; Buczkowski, Kevin A. ; Richards, William G. ; Gandhi, Leena ; Redig, Amanda J. ; Rodig, Scott J. ; Asahina, Hajime ; Jones, Robert E. ; Kulkarni, Meghana M. ; Kuraguchi, Mari ; Palakurthi, Sangeetha ; Fecci, Peter E. ; Johnson, Bruce E. ; Janne, Pasi A. ; Engelman, Jeffrey A. ; Gangadharan, Sidharta P. ; Costa, Daniel B. ; Freeman, Gordon J. ; Bueno, Raphael ; Hodi, F. Stephen ; Dranoff, Glenn ; Wong, Kwok Kin ; Hammerman, Peter S. / Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. In: Nature Communications. 2016 ; Vol. 7.
@article{30faed313b1d4ad98a567fc71cd87436,
title = "Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints",
abstract = "Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidate mechanisms of adaptive resistance, we analyse the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma. In tumours progressing following response to anti-PD-1 therapy, we observe upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3), in PD-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade. Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure. These data suggest that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.",
author = "Shohei Koyama and Akbay, {Esra A.} and Li, {Yvonne Y.} and Herter-Sprie, {Grit S.} and Buczkowski, {Kevin A.} and Richards, {William G.} and Leena Gandhi and Redig, {Amanda J.} and Rodig, {Scott J.} and Hajime Asahina and Jones, {Robert E.} and Kulkarni, {Meghana M.} and Mari Kuraguchi and Sangeetha Palakurthi and Fecci, {Peter E.} and Johnson, {Bruce E.} and Janne, {Pasi A.} and Engelman, {Jeffrey A.} and Gangadharan, {Sidharta P.} and Costa, {Daniel B.} and Freeman, {Gordon J.} and Raphael Bueno and Hodi, {F. Stephen} and Glenn Dranoff and Wong, {Kwok Kin} and Hammerman, {Peter S.}",
year = "2016",
month = "2",
day = "17",
doi = "10.1038/ncomms10501",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

AU - Koyama, Shohei

AU - Akbay, Esra A.

AU - Li, Yvonne Y.

AU - Herter-Sprie, Grit S.

AU - Buczkowski, Kevin A.

AU - Richards, William G.

AU - Gandhi, Leena

AU - Redig, Amanda J.

AU - Rodig, Scott J.

AU - Asahina, Hajime

AU - Jones, Robert E.

AU - Kulkarni, Meghana M.

AU - Kuraguchi, Mari

AU - Palakurthi, Sangeetha

AU - Fecci, Peter E.

AU - Johnson, Bruce E.

AU - Janne, Pasi A.

AU - Engelman, Jeffrey A.

AU - Gangadharan, Sidharta P.

AU - Costa, Daniel B.

AU - Freeman, Gordon J.

AU - Bueno, Raphael

AU - Hodi, F. Stephen

AU - Dranoff, Glenn

AU - Wong, Kwok Kin

AU - Hammerman, Peter S.

PY - 2016/2/17

Y1 - 2016/2/17

N2 - Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidate mechanisms of adaptive resistance, we analyse the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma. In tumours progressing following response to anti-PD-1 therapy, we observe upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3), in PD-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade. Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure. These data suggest that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.

AB - Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer, resistance to these therapies has increasingly been observed. In this study, to elucidate mechanisms of adaptive resistance, we analyse the tumour immune microenvironment in the context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma. In tumours progressing following response to anti-PD-1 therapy, we observe upregulation of alternative immune checkpoints, notably T-cell immunoglobulin mucin-3 (TIM-3), in PD-1 antibody bound T cells and demonstrate a survival advantage with addition of a TIM-3 blocking antibody following failure of PD-1 blockade. Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure. These data suggest that upregulation of TIM-3 and other immune checkpoints may be targetable biomarkers associated with adaptive resistance to PD-1 blockade.

UR - http://www.scopus.com/inward/record.url?scp=84958555198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958555198&partnerID=8YFLogxK

U2 - 10.1038/ncomms10501

DO - 10.1038/ncomms10501

M3 - Article

C2 - 26883990

AN - SCOPUS:84958555198

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10501

ER -